Panacea Biotec Limited (BOM:531349)

Market Cap	21.44B +1.4%
Revenue (ttm)	6.06B +7.6%
Net Income	-77.80M
EPS	-1.28
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,792
Average Volume	7,503
Open	353.90
Previous Close	356.50
Day's Range	347.00 - 360.75
52-Week Range	282.15 - 581.00
Beta	n/a
RSI	42.01
Earnings Date	Feb 11, 2026

About Panacea Biotec

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1984
• Employees: 2,149
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531349

Financial Performance

In fiscal year 2025, Panacea Biotec's revenue was 5.59 billion, a decrease of -0.01% compared to the previous year's 5.59 billion. Losses were -83.70 million, 613.6% more than in 2024.